Abstract
At the beginning of the twentieth century, a newly diagnosed diabetic patient had a life expectancy of 44 years. Little could be offered to treat diabetes except for dietary restriction and starvation, and death from hyperglycemic coma was common. After the discovery of insulin in 1921, the average age life expectancy in patients with diabetes rapidly increased to 61 years, death rates from coma declined, while death from cardiovascular disease, gangrene, and renal complications began to increase [1]. Diabetes research, for many years to follow, focused on understanding the pathophysiology behind diabetes and its complications, and the development of new treatments and technologies to improve the care of diabetic patients. Improvements in sanitation in the early 1900s resulted in an increase in life expectancy for the entire population, and by 1933, it was already recognized that the risk of developing diabetes increased with advancing age. In addition to advancing age, it was also noted that genetics and obesity contributed to one’s risk of developing diabetes. The social changes at the time allowed easier access to food, and the transition of labor from manual to mechanical in both urban and rural societies led greater numbers of people becoming overweight. Therefore, as the population was living longer and becoming more overweight, it was predicted that a rise in the incidence of diabetes was inevitable [2]. By the end of the twentieth century, diabetes was being described as a global epidemic. Life expectancy continued to rise; the social changes leading to overconsumption of food and an increasingly sedentary lifestyle caused the rates of obesity to escalate worldwide (Fig. 1.1). As diabetes and its complications could be effectively managed with modern medicine, the cost of diabetes care was growing annually. Therefore, in the twenty-first century, the focus of diabetes care is shifting toward diabetes prevention. In 1933, Joslin commented that diabetes is not a contagious disease and is a disease for the doctor to treat, rather than the state, the city, or the boards of health. However, given the extent of the current diabetes epidemic, professional societies, health boards, and government are becoming increasingly involved in diabetes prevention and there have been suggestions that the epidemic should be addressed in a similar manner to the outbreak of an infectious disease [3].
Keywords
- Oral Glucose Tolerance Test
- Impaired Glucose Tolerance
- American Diabetes Association
- Impaired Fasting Glucose
- Diabetes Prevention
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Joslin EP. Heredity and prevention. Bull N Y Acad Med. 1933;9(9):532–7.
Mosenthal HO. Diabetes mellitus—problems of present day treatment. Bull N Y Acad Med. 1933;9(9):505–22.
Matthews DR, Matthews PC. Type 2 diabetes as an ‘infectious’ disease: is this the Black Death of the 21st century? Diabet Med. 2011;28:2–9.
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025. Diabetes Care. 1998;21:1414–31.
Wild D, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care. 2004;27:1047–53.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.
Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
Kitagawa T, Owada M, Urakami T, Yamanchi K. Increased incidence of non-insulin dependent diabetes mellitus among Japanese school children correlates with an increased intake of animal protein and fat. Clin Pediatr. 1998;37:111–6.
Dabelea D, Knowler WC, Pettitt DJ. Effect of diabetes in pregnancy on offspring: follow-up research in Pima Indians. J Matern Fetal Med. 2000;9(1):83–8.
Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28:2130–5.
Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. Diabetes Res Clin Pract. 2010;87(1):15–9.
Zhang P, Zhang X, Brown J, Vistisen D, Sicree J, Nichols G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3):293–301.
IDF Diabetes Atlas. The global burden, 4th ed. Brussels: International Diabetes Federation; 2009. p. 21–7.
Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes and cardiovascular risk in children. Circulation. 2003;107:1448–53.
De Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA. 2001;285:2109–13.
DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003;26:688–96.
Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care. 2003;26:2910–4.
Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care. 1999;22:1262–5.
American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34 Suppl 1:S11–61.
WHO Consultation. Use of glycated haemoglobin (HbA1C) in the diagnosis of diabetes mellitus. 2011. http://www.who.int/cardiovascular_diseases/report-hba1c_2011_edited.pdf. Accessed May 2011.
American Association of Clinical Endocrinologists Board of Directors; American College of Endocrinologists Board of Trustees. American Association of Clinical Endocrinologists/American College of Endocrinology Statement on the use of hemoglobin A1c for the diagnosis of diabetes. Endocr Pract. 2010;16(2):155–6.
WHO. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva, Switzerland: WHO Press; 2006.
Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P. Impace of HbA1c screening criteria on the diagnosis of pre-diabetes among US adults. Diabetes Care. 2010;33(10):2190–5.
James C, Bullard KM, Rolka DB, Geiss LS, Williams DE, Cowie CC, et al. Implications of alternative definitions of prediabetes for prevalence in US adults. Diabetes Care. 2011;24(2):387–91.
Buse JB. Screening for diabetes and prediabetes with proposed A1c-based diagnostic criteria. Diabetes Care. 2010;33(12):e174.
Bonora E, Tuomilehto J. The Pros and Cons of diagnosing diabetes with A1c. Diabetes Care. 2011;34 Suppl 2:S184–90.
Malkani S, Mordes JP. Implications of using hemoglobin A1c for diagnosing diabetes mellitus. Am J Med. 2011;124:395–401.
Flegal KM, Carroll M, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–41.
Zhang Q, Wang Y, Huang ES. Changes in racial/ethnic disparities in the prevalence of type 2 diabetes by obesity level among US adults. Ethn Health. 2009;14(5):439–57.
Lee JWR, Brancati FL, Yeh HC. Trends in the prevalence of type 2 diabetes in Asians versus whites. Diabetes Care. 2011;34:353–7.
Hutley L, Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci. 2005;330(6):280–9.
Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–607.
Lear SA, Humphries SK, Birmingham CL. The use of BMI and waist circumference as surrogates of body fat differs by ethnicity. Obesity. 2007;15:2817–24.
Gilles CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;344(7588):299–307.
De la Cruz-Munoz N, Messiah SE, Arheart KL, Lopez-Mitnik G, Lipshultz SE, Livingstone A. Bariatric surgery significantly decreases the prevalence of type 2 diabetes mellitus and pre-diabetes among morbidly obese multiethnic adults: long term results. J Am Coll Surg. 2011;212:505–13.
Alberti KGMM, Zimmet P, Shaw J. International diabetes federation: a consensus on type 2 diabetes prevention. Diabet Med. 2007;24:451–63.
Egger J, Dixon J. Non-nutrient causes of low-grade, systemic inflammation: support for ‘a canary in the mineshaft’ view of obesity in chronic disease. Obes Rev. 2011;12:339–45.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gallagher, E.J., LeRoith, D. (2012). Prevention of Type 2 Diabetes; from Science to Therapies. In: LeRoith, D. (eds) Prevention of Type 2 Diabetes. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3314-9_1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3314-9_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3313-2
Online ISBN: 978-1-4614-3314-9
eBook Packages: MedicineMedicine (R0)